특징
Claudin 18.2 (CLDN18.2)는 최근 항암제 연구, 특히 위암 및 췌장암 치료 분야에서 가장 주목받고 있는 표적 단백질(타겟) 중 하나입니다. Claudin 중에서도 18.2번(CLDN18.2) 아형은 매우 독특한 발현 특징을 가지고 있습니다. 정상 조직에서는 오직 위점막의 분화된 세포에서만 제한적으로 발견되거나 세포 내에 깊숙하게 숨겨져 있지만, 위암, 췌장암, 식도암, 담도암 등이 발생하면 세포 구조가 무너지면서 숨겨져 있던 CLDN18.2가 세포 표면 밖으로 훤히 노출되므로, 정상 세포는 다치지 않게 보호하면서 암세포만 정밀 타격하기에 완벽한 조건을 갖추고 있습니다.
Tight junction은 상피세포 사이의 세포 간 공간을 통과하는 분자의 흐름을 조절하는 세포 간 장벽을 형성합니다. Claudin (클라우딘)은 이 타이트 정션의 핵심 구성 요소로, 약 20~27 kDa 크기의 막단백질이며 보통 4개의 막 관통 도메인과 2개의 세포 외 루프를 가집니다. 약 27종의 클라우딘 단백질이 조직별로 다르게 분포하며, 이들의 기능 이상은 여러 암과 연관되어 있어 진단 및 치료의 잠재적 표적이 됩니다.
- Claudin 18 isoform 2 (CLDN18.2)는 정상시에 위 점막 상피세포에서만 발현되는 단백질이지만, 선암, 췌장암, 식도암, 폐암등과 같은 특정암 발생시 과발현됩니다. 이러한 비정상적인 발현은 CLDN18.2가 종양의 침습 및 전이에 중요한 역할을 할 수 있음을 시사합니다.
- CLDN18.2는 일차 위선암과 그 전이암의 50~70%에서 발현되기 때문에, 위암 표적 치료의 유망한 후보로 간주됩니다.
- Claudin 18.2 (CLDN18.2)를 발현하는 CHO, HEK 세포주 및 단백질과 항체를 제공합니다.
- CLDN18.2와 binding하는 약물 후보의 선별에 이용됩니다.
주요 제품
1. CHO-K1/CLDN18.2 Stable Cell Line (#M00916)
- Clonality : Single clone
- Stability : Stable expression of CLDN18.2 for more than 15 passages
- Culture condition :
- Freeze Medium : 72% F12k, 20% FBS, 8% (V/V) DMSO
- Culture Medium : F12K, 10% FBS, 500μg/ml Geneticin (G418 Sulfate)
2. HEK293/CLDN18.2 Stable Cell Line (#M00917)
- Clonality : Single clone
- Stability : Stable expression of CLDN18.2 for more than 15 passages
- Culture condition :
- Freeze Medium : 49% DMEM, 45% FBS, 6% (V/V) DMSO
- Culture Medium : DMEM, 10% FBS,500μg/ml(G418 Sulfate) Geneticin (G418 Sulfate)
3. MonoRab™ Claudin 18.2 Antibody (126C1), mAb, Rabbit (#A02180)
- Clonality : Monoclonal
- Clone ID : 126C1
- Host Species : Rabbit
- Immunogen : Recombinant Human Claudin 18.2 Protein and DNA
- Conjugate : Unconjugated
- Form : Liquid
- Storage Buffer : Supplied in PBS, pH 7.4, containing 0.02% ProClin300
- Concentration : 1.5 mg/mL
4. CLDN18.2 Protein (#Z03504)
- Species : Human
- Protein Construction : Poly-His CLDN18.2 (Met1-Lys207)
- Accession : P56856-2
- Purity: > 80% as analyzed by SDS-PAGE
- Biological Activity : Immobilized CLDN18.2, His, Human (Cat. No.: Z03504) at 1.0 μg/mL (100μl/well). Dose response curve for anti-Claudin 18.2 Antibody with the EC50 of 13.75ng/mL determined by ELISA.
- Expression System : Insect Cells
- Theoretical Molecular Weight : 27.7 kDa
- Formulation : Supplied as a solution in 50 mM Hepes, 500 mM NaCl, 10% glycerol, 0.2% DDM, 0.04% CHS, pH 7.5.
참고 데이터
그림 1. Bioactivity of CLDN18.2, hFc, Human (Cat. No.: Z03709) was validated by ELISA. Immobilized anti-Claudin 18.2 antibody was at 1 μg/mL (100 μL/well). Dose response curve for CLDN18.2, hFc, Human with the EC50 of 17.60 ng/ml was determined by ELISA. CLDN18.2, hFc, Human was found to be an active membrane protein.
그림 2. Cell based ELISA with CHO-K1/CLDN 18.2 cell line (Cat. No.: M00916). CHO-K1/CLDN18.2 cells were plated at 8x104 cells /well in 100 μl DMEM plus with 10% FBS in 96-well plate overnight. Then the cells were fixed with paraformaldehyde for 15 minutes. After washing, the cells were incubated with gradient concentration of IMAB-362 (anti-CLDN18.2 antibody) for 1 hour, and incubated with goat anti-human IgG (H&L) [HRP] antibody. After incubation with TMB substrate, OD450 was measured by a microplate reader.
그림 3. Cell-based binding assay with CHO-K1/CLDN 18.2 stable cell line (Cat. No.: M00916). CHO-K1/CLDN18.2 cells were plated at 5x105 cells/well in 100 µL of PBS in 96-well plate, incubated with gradient concentration of IMAB-362 (anti-CLDN18.2 antibody) on ice for 1 hour. The supernatant was discarded and the cells were incubated with goat anti-human IgG antibody at 10 µg/mL on ice for 1 hour. The mean fluorescence intensity of APC (Mean APC-H) was analyzed in live cell gate by a flow cytometer .
그림 4. The purity of CLDN18.2, His, Human (Cat. No.: Z03504) was assessed by SDS-PAGE. Purity > 90% was observed for 2 μg of protein.
(Lane BSA: 2 μg BSA, Lane R: 2 μg CLDN18.2, reducing (R), no heat treatment before loading.)
그림 5. Protein expression of CLDN18.2 was validated in HEK293/CLDN18.2 stable cell line (Cat. No.: M00917) using FACS. The FACS analysis of CLDN18.2 expression in HEK293/ CLDN18.2 clone was conducted using anti-CLDN18.2 antibody. The cells analyzed were live cells (E1 gate). (Green line: negative control, treated with goat anti-human IgG antibody. Red line: tested sample, treated with anti-CLDN18.2 antibody.)
그림 6. Stability of CLDN18.2 expression in HEK293/CLDN18.2 stable cell line (Cat. No.: M00917) was tested using FACS. The stability of expression was tested for cell samples from 20 passages using anti-CLDN18.2 antibody. The cells analyzed were live cells (E1 gate). (Blue line: blank control, untreated cells. Purple line: negative control, treated with goat anti-human IgG antibody. Experimental group: cell samples of different passages.)